IIT Delhi researcher develop next-gen vaccine using body's own immune cells

It was found that this antigen was more effective than free antigens in producing antibodies against the Covid-19 virus

IANS New Delhi
Day 1: IIT Guwahati bags highest foreign job offer of Rs 2.4 crore

IIT Delhi

Researchers at IIT-Delhi on Thursday said they developed a nano-vaccine using the body's own immune cells, as opposed to the synthetic materials or adenoviruses used in Covid-19 vaccines.

This naturally derived nano-vaccine developed by researchers may have several advantages over currently approved vaccines. It will reduce the possibility of blood clotting, which has previously been observed in vaccinated individuals, according to IIT-Delhi.

The immune response elicited by this vaccine was tested in mice.

It was found that this antigen was more effective than free antigens in producing antibodies against the Covid-19 virus.

"In fact, when injected with a 10 times lower dose compared to the free antigen, the nano-vaccine was equally efficient in raising antiviral immunity. Interestingly, it showed a durable immune response, including the generation of memory cells, which can act as a safeguard for the next infection," Prof Jayanta Bhattacharyya, Centre for Biomedical Engineering, IIT-Delhi, said in a statement.

In general, after vaccination, antigen-presenting cells (APCs) begin processing the antigens and subsequently activate other immune cells (B and T cells) to produce antibodies, and eliminate the virus, said IIT-Delhi.

Also Read

Researchers develop new approach to find immune cell-triggering antigens

IIT JAM 2023: How to apply, eligibility criteria, registration and more

IIT Roorkee announces development of low-cost solar cells by researchers

Study explores how common immune cells might prevent intestinal healing

Researchers in US develop drug that marks cancer cells for elimination

Global sea level rose by 4.5 mm per year during 2013-22 period: WMO

Actual Covid infections in India 17 times higher than reported: BHU study

India adopting environment-friendly development model: Sultan Al Jaber

G20 working group meeting to discuss climate change, land degradation

How the dodo might return with the Nicobar pigeon as its surrogate mother

This next-generation vaccine, however, is one step ahead since it uses nanovesicles from activated APCs, which already contain processed antigens on their surface and are also equipped with additional factors needed to directly activate B and T cells, it added.

Prof Bhattacharyya also mentioned that this approach to vaccination can be used for various other infectious diseases, such as dengue.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Feb 16 2023 | 6:58 PM IST

Explore News